Verified
I used the prescribed amount at night. The first few applications caused mild stinging, but intercourse was less uncomfortable after several weeks. The discharge was more noticeable than I expected.
15 Sept 2026
Active ingredient: Estriol
Estriol
Quality products
24/7 Support
Fast delivery
Delivery
from 4 days
Estriol is a local vaginal oestrogen cream for adults with menopausal vaginal and urinary symptoms. Its active ingredient replaces some of the oestrogen lost after menopause and helps restore moisture, tissue strength, and comfort in affected urogenital tissues.
Description
Estriol is a locally applied oestrogen cream for adults with menopausal vaginal and urinary symptoms. It is used when reduced oestrogen causes dryness, irritation, tissue thinning, or painful intercourse. Applied inside the vagina, estriol supports the tissues most affected by oestrogen loss.
Composition
Estriol is a naturally occurring oestrogen and the active ingredient in this cream. The product contains estriol 0.01% w/w in a vaginal cream supplied in a tube with an applicator. Its purpose is local treatment of tissues affected by declining oestrogen during Menopause.
Dosage and usage
Use the prescribed amount and schedule for this estriol cream. The appropriate regimen depends on the severity of symptoms, previous treatment, age, medical history, and the product’s applicator calibration.
Clinical regimens commonly contain two phases:
- An initial period of more frequent vaginal application to restore the atrophic lining.
- A maintenance schedule with less frequent application after symptoms improve.
- Reassessment when bleeding, persistent pain, or new pelvic symptoms occur.
- Continued treatment when symptoms return after stopping, if the prescriber considers it appropriate.
If an application is missed, use it when remembered unless the next scheduled application is close. Do not apply a double amount to compensate. Keep the cream away from the eyes and avoid applying it to broken external skin unless specifically instructed.
Using the cream at bedtime can reduce leakage and gives the product longer contact with vaginal tissue. A thin sanitary liner may be useful during the first few applications.
How it works
Oestrogen receptors are present in the vaginal lining, vulva, urethra, and bladder base. When oestrogen levels fall, the vaginal epithelium becomes thinner, less elastic, and less well hydrated. Blood flow and natural lubrication may also decrease. Estriol binds to oestrogen receptors in these tissues and encourages maturation of the vaginal lining, improved moisture, and a more acidic environment that supports normal vaginal health.
Estriol has a shorter and weaker oestrogenic profile than Estradiol. Its receptor activity is useful for local symptoms, while systemic exposure is generally lower than with oral or transdermal hormone treatment. Absorption can still occur, especially during the first weeks when the vaginal lining is thin, so treatment remains a hormonal therapy rather than a non-hormonal moisturiser. [1]
Biological role of oestrogen in urogenital tissues
Oestrogen helps maintain:
- Vaginal epithelial thickness and elasticity.
- Natural lubrication and comfort during movement or sexual activity.
- Healthy vaginal acidity and microbial balance.
- Blood flow to the vulvovaginal and urethral tissues.
- Tissue resilience around the lower urinary tract.
Vaginal dryness can continue even when hot flushes have stopped. Local oestrogen targets the pelvic tissues directly, so symptom timing does not always match other menopausal symptoms.
Indications
Estriol cream is used for symptoms linked to Vaginal Atrophy, also called genitourinary syndrome of menopause. Vaginal atrophy is caused by reduced oestrogen after menopause, although similar tissue changes can occur after ovarian surgery, some cancer treatments, or prolonged suppression of ovarian function.
Common symptoms include dryness, burning, itching, soreness, reduced lubrication, and Painful Intercourse. Some patients also develop urinary urgency, recurrent urinary discomfort, or increased sensitivity around the urethra. Local oestrogen may improve the tissue changes behind these symptoms, but it does not treat every cause of pelvic pain or urinary symptoms. [2]
| Symptom | How local estriol may help |
|---|---|
| Vaginal dryness or burning | Supports epithelial maturation, moisture, and local blood flow |
| Itching or soreness | Helps restore thinner, more fragile vaginal tissue |
| Painful intercourse | Improves lubrication and tissue flexibility over time |
| Urinary urgency or recurrent discomfort | Supports oestrogen-sensitive urethral and bladder-base tissues |
Improvement is gradual. Burning and irritation may settle before tissue flexibility fully returns. Pain with intercourse can also involve pelvic-floor tension, infection, dermatological conditions, or endometriosis, which require separate assessment.
Comparison
Estriol and Estradiol are both oestrogens, but they differ in potency, receptor activity, and clinical use. Estradiol has stronger and longer-lasting oestrogenic activity. It is available in local and systemic treatments, including vaginal products, patches, gels, and tablets.
Estriol is commonly selected when symptoms are concentrated in the vagina, vulva, or lower urinary tract. Estradiol may be preferred when a stronger local effect is needed or when systemic menopausal symptoms also require treatment. The choice depends on symptoms, medical history, previous hormone exposure, and treatment goals. [3]
| Treatment | Main use and exposure |
|---|---|
| Estriol cream | Local vaginal symptoms; generally lower systemic exposure than systemic therapy |
| Local vaginal estradiol | Local vaginal symptoms; stronger oestrogenic activity may be preferred in some cases |
| Systemic HRT | Hot flushes, night sweats, and wider menopausal symptoms; greater circulating hormone exposure |
“Stronger” does not automatically mean “better.” A clinician may choose the lowest oestrogen exposure that addresses the symptoms. Estriol may suit a person whose main problem is vaginal dryness, while systemic HRT may be considered when symptoms affect sleep, temperature regulation, mood, or daily functioning.
Local vaginal oestrogen and systemic hormone replacement therapy
Local Vaginal Oestrogen delivers hormone to the vulvovaginal and lower urinary tissues. Systemic HRT delivers hormones into the bloodstream through tablets, patches, gels, or other routes, allowing them to act throughout the body.
Local treatment is often considered when symptoms are exclusively urogenital. It usually produces less circulating oestrogen than systemic treatment, although measurable absorption is possible. The amount absorbed may be higher during the initial phase because atrophic tissue is thinner and more permeable.
Systemic HRT can help vasomotor symptoms such as hot flushes and night sweats. Local estriol cream does not provide equivalent treatment for those symptoms. A person may use local therapy alone, or a local preparation alongside systemic HRT, when vaginal symptoms persist despite improvement in other menopausal complaints.
“Bioidentical” describes a hormone whose molecular structure is identical to a hormone produced by the human body. Estriol and Estradiol can both be bioidentical in chemical structure. The term does not prove that a product has greater safety, stronger results, or better monitoring.
Contraindications
Avoid use unless a specialist has specifically directed otherwise if you have:
- Known, previous, or suspected breast cancer.
- Known or suspected oestrogen-dependent cancer, including endometrial cancer.
- Unexplained vaginal bleeding.
- Untreated endometrial hyperplasia.
- Previous or current venous thromboembolism, such as deep-vein thrombosis or pulmonary embolism.
- Active or recent arterial thromboembolic disease, including myocardial infarction or stroke.
- Severe liver disease while liver function remains abnormal.
- A known allergy to estriol or an excipient in the cream.
- Porphyria that is triggered by hormones.
- Pregnancy or suspected pregnancy.
A history of breast cancer, ovarian cancer, endometrial cancer, thrombosis, liver disease, migraine with neurological symptoms, or uterine fibroids requires an individual risk assessment. Tamoxifen and aromatase inhibitors also require specialist coordination because local oestrogen can be clinically relevant in hormone-sensitive cancer care.
Unexplained bleeding needs assessment before treatment begins. Bleeding that develops after a period of treatment also needs prompt medical review, especially if it is recurrent, heavy, or occurs after intercourse. NICE guidance and the European Medicines Agency place emphasis on investigating postmenopausal bleeding rather than attributing it automatically to vaginal atrophy. [4]
When this is not for you
This treatment may not be suitable if you have had breast or other hormone-dependent cancer, unexplained vaginal bleeding, blood clots, stroke, heart attack, severe liver disease, hormone-triggered porphyria, or an allergy to estriol or another cream ingredient. Do not use it during pregnancy or suspected pregnancy without specialist direction. Tell your clinician about migraine with neurological symptoms, uterine fibroids, cancer treatment, or medicines such as tamoxifen and aromatase inhibitors.
Side effects
Most adverse effects are local. They may occur during the first applications and settle as the vaginal tissue becomes less fragile.
Possible effects include:
- Temporary burning, stinging, itching, or irritation.
- Increased vaginal discharge.
- Vaginal spotting or light bleeding.
- Breast tenderness or breast fullness.
- Headache, nausea, or fluid retention.
- Worsening of migraine in susceptible people.
- Allergic skin or mucosal reaction.
Stop treatment and obtain urgent medical attention for sudden chest pain, breathlessness, one-sided leg swelling, severe headache with neurological symptoms, jaundice, or a new breast lump. These symptoms can have causes unrelated to estriol, but they require assessment.
Local therapy does not eliminate hormone-related risks. The risk profile depends on dose, duration, absorption, personal history, and whether other hormone treatments are used. Persistent irritation may indicate contact sensitivity, infection, vulval skin disease, or incorrect application rather than a need for more cream.
A small amount of discharge after vaginal cream is common because the base melts at body temperature. Persistent foul-smelling discharge, pelvic pain, or fever points to a different problem and needs assessment.
Common mistakes
Poor results often come from application problems rather than lack of oestrogen response.
- Stopping after the first comfortable week instead of completing the prescribed initial phase.
- Applying extra cream after a missed dose.
- Using the cream only before intercourse rather than on the scheduled regimen.
- Inserting the applicator forcefully when tissue is painful or narrowed.
- Treating recurrent discharge or odour as ordinary cream residue.
- Ignoring postmenopausal bleeding.
- Adding over-the-counter vaginal products that cause irritation.
- Forgetting to mention local oestrogen before breast cancer treatment or surgery.
- Assuming local treatment will relieve hot flushes or sleep disturbance.
- Continuing treatment despite a clear allergic reaction.
Keep a simple symptom record for dryness, burning, urinary discomfort, bleeding, and painful intercourse. Changes over several weeks are more useful than judging the cream after one application.
What doctors say
In clinical practice, doctors often separate vaginal symptoms from whole-body menopausal symptoms before selecting treatment. A patient with dryness, burning, or painful intercourse may need local therapy even when hot flushes are mild. A patient with severe night sweats and vaginal symptoms may need a broader treatment plan.
Clinicians also look for reversible contributors. Antibiotics, recurrent candidiasis, dermatological disease, pelvic-floor spasm, low sexual arousal, and some cancer treatments can all produce discomfort that resembles vaginal atrophy.
A practical prescribing conversation usually covers:
- The main symptom and how long it has been present.
- Any bleeding after menopause or after intercourse.
- Personal and family history of breast or endometrial cancer.
- Previous blood clots, stroke, heart disease, or liver disease.
- Current HRT, cancer treatment, anticoagulants, and vaginal products.
- The intended induction and maintenance schedule.
Many patients expect improvement after one or two applications. Tissue recovery usually takes longer, and comfort may improve in stages. A clinician may review the response after the initial treatment period and adjust frequency rather than simply increasing the amount. Follow-up should consider symptom relief, adverse effects, bleeding, and continued treatment needs. The regimen can then be maintained, reduced, or reassessed according to the clinical response.
Frequently asked questions
How long does Estriol cream take to work?
Some people notice less dryness or burning within the first few weeks, while tissue recovery may take longer. The National Institute for Health and Care Excellence (2024) describes local vaginal oestrogen as a treatment that may require ongoing use when symptoms return after stopping. Response should be judged by comfort, discharge, urinary symptoms, and bleeding patterns rather than by one application.
Can Estriol cream help painful intercourse?
Estriol may help when painful intercourse is caused by dryness, thin vaginal tissue, or reduced elasticity. The International Menopause Society (2022) identifies genitourinary symptoms as a common consequence of declining oestrogen and supports local treatment when appropriate. Pain that persists despite improved lubrication may involve pelvic-floor tension, infection, vulval disease, or another pelvic condition.
Does local Estriol cream enter the bloodstream?
A portion can be absorbed into the bloodstream, especially during the initial phase when vaginal tissue is thin. The European Medicines Agency (2014) describes local vaginal oestrogen as having lower systemic exposure than systemic HRT, rather than zero absorption. Personal risk remains relevant in people with hormone-sensitive cancer, thrombosis, liver disease, or unexplained bleeding.
Can Estriol be used with systemic HRT?
Local estriol may be prescribed alongside systemic HRT when vaginal symptoms continue despite treatment of hot flushes and night sweats. NICE guidance updated in 2024 supports considering local vaginal oestrogen for genitourinary symptoms, including in people using systemic treatment. The combined plan should account for the total hormone exposure and personal contraindications.
Is Estriol suitable after breast cancer?
Suitability after breast cancer depends on the cancer’s hormone sensitivity, current treatment, recurrence risk, and severity of symptoms. The National Comprehensive Cancer Network (2024) and specialist menopause guidance recommend coordinated decision-making for survivors, especially those using aromatase inhibitors or tamoxifen. Unsupervised use is inappropriate in this situation.
Can Estriol cream cause bleeding?
Light spotting can occur, especially when fragile vaginal tissue is first treated. The South African Health Products Regulatory Authority (2024) and international prescribing standards require unexplained postmenopausal bleeding to be assessed rather than automatically attributed to treatment. New, heavy, recurrent, or persistent bleeding needs prompt clinical evaluation.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Bioidentical hormone therapy and estriol
Estriol is chemically identical to human estriol when produced to pharmaceutical standards. This is the biochemical meaning of bioidentical. It does not mean that every compounded formulation has the same quality control, dose consistency, or clinical evidence as a regulated medicine.
Progesterone is another naturally occurring hormone and may also be described as bioidentical when its molecular structure matches human progesterone. Its role differs from estriol. Progesterone protects the endometrium during systemic oestrogen therapy in people with a uterus; it is not a substitute for local estriol treatment.
Compounded hormone preparations may combine hormones or use personalised concentrations. Their quality, absorption, and clinical evidence can vary. Regulated products have defined active ingredients and manufacturing controls, while the term bioidentical alone does not establish a treatment’s suitability. The British Menopause Society and international menopause guidance support evidence-based prescribing rather than relying on the word bioidentical as a quality claim. [5]
Estriol: Reviews and Experiences
3.4
Based on 4 reviews
Verified
Dryness and burning improved gradually, and I needed less lubricant. I missed doses during a busy week and did not double the next application. Symptoms settled again after returning to the prescribed routine.
23 Sept 2026
Verified
The cream helped vaginal soreness but did not change my hot flushes or poor sleep. My clinician explained that local treatment was aimed at the pelvic symptoms, so another plan was needed for the rest.
29 Sept 2026
Verified
I developed spotting after treatment had been comfortable for some time. It turned out that the bleeding needed investigation, so I stopped applying the cream until I had been assessed.
11 Oct 2026
Sources
- European Medicines Agency (2014). Guideline on the assessment of medicinal products for the treatment of menopausal symptoms.
- National Institute for Health and Care Excellence (2024). Menopause: identification and management, NG23.
- The 2022 Hormone Therapy Position Statement Advisory Panel (2022). The 2022 hormone therapy position statement of The North American Menopause Society.
- European Medicines Agency (2014). Guideline on clinical investigation of medicinal products for the treatment of menopausal symptoms.
- British Menopause Society (2023). The 2023 British Menopause Society and Women’s Health Concern recommendations on hormone replacement therapy.
